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Abstract
Background To elucidate the evolution of a lung-sparing strategy with sleeve lobectomy (SL) and induction
therapy for non-small cell lung cancer (NSCLC).
Methods We retrospectively reviewed 205 patients with NSCLC who underwent pneumonectomy (PN, n = 54) or
SL (n = 151) from 1994 to 2013. The study period was divided into four 5-year periods, and surgical trends were
analyzed, focusing on the PN:SL ratio.
Results PN was associated with a significantly advanced pathological stage, a larger tumor size and less pulmonary
function compared with SL. The PN group had higher 30-day (3.7 vs. 0 %, p = 0.018) and 90-day (13.0 vs. 1.3 %,
p = 0.0003) mortality than the SL group. The overall 5-year survival rate was significantly higher with SL (71.5 %)
versus PN (42.8 %, p = 0.011) for patients with pN0–1. The ratio of PN among total surgeries decreased signifi-
cantly over the four periods (1994–1998, 1999–2003, 2004–2008, and 2009–2013) from 5.63 % to 3.17, 1.40, and
1.38 %, respectively (p\ 0.0001); in contrast, the PN:SL ratio increased significantly from 1.64 to 2.50, 3.71, and
5.44, respectively (p = 0.041). During the last period, when we introduced induction therapy, 38 of 651 who
received surgery underwent induction therapy. The PN:SL ratios of those who did and did not undergo induction
therapy were 15 (PN: 1, SL: 15) and 4.25 (PN: 8, SL: 34), respectively.
Conclusions A lung-sparing strategy with SL for NSCLC can decrease the PN rate to less than 2 % with less
mortality. Induction therapy may facilitate SL and increase the PN:SL ratio.
Introduction
The purpose of surgical resection for non-small cell lung
cancer (NSCLC) is to achieve complete resection of the
tumor and lymph nodes to maximize the possibility of cure.
Bronchial and/or pulmonary arterial sleeve lobectomy (SL)
is a lung parenchyma-sparing procedure that aims for
complete resection of tumors invading the central
structures. SL was originally indicated for patients with
reduced pulmonary function, who were intolerant of
pneumonectomy (PN). However, SL is now indicated even
for patients with sufficient pulmonary function to avoid
PN, which causes substantial loss of pulmonary function
and thus quality of life. Much evidence has been accu-
mulated that the long-term survival after SL is favorable to
that of PN, with lower mortality and morbidity [1–7]. A
recent meta-analysis by Shi et al. demonstrated that SL
provides lower mortality, better long-term survival, less
loss of function, and better quality of life than PN without
increasing morbidity and locoregional recurrences [8].
These results have encouraged surgeons to pursue lung
parenchyma-sparing strategies more aggressively [2, 9–
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12]. Go´mez-Caro and colleagues have reported their
aggressive policy of avoiding PN by determining the
appropriate PN to SL (PN:SL) ratio, which might reflect
the institutes’ lung-sparing policy [13].
Induction therapy has been increasingly used for locally
advanced NSCLC to downstage tumors and to facilitate
complete resection. However, very few studies have com-
pared outcomes of SL and PN after induction therapy [14,
15]. Maurizi et al. reported that SL represented a valid
therapeutic option even after induction therapy, providing
better long-term survival than PN with no increase in
morbidity or recurrence [14]. Rendina and coworkers
suggested that induction therapy may facilitate SL, reduc-
ing the need for PN while maintaining the completeness of
resection [16].
We perform SL to avoid PN whenever it is technically
and oncologically feasible, even for patients with sufficient
pulmonary function. In this retrospective study, we
reviewed the outcomes of PN and SL in our institute and
elucidated the evolution of a lung-sparing strategy to avoid
PN with SL and induction therapy.
Materials and methods
We retrospectively reviewed the clinical records of 205
patients with NSCLC who underwent PN (n = 54) or SL
(n = 151) at our institution from January 1994 to
December 2013. During the same period, 2047 patients
with NSCLC underwent surgery at our institution. The
20-year study period was then divided into four periods of
5 years each, and the trends in surgical strategy were
analyzed, focusing on the PN:SL ratio. The Ethics Com-
mittee of Chiba University approved this study and granted
a waiver for patient consent.
The preoperative work-up for all patients included phys-
ical examination, chest radiography, contrast-enhanced
thoracic, upper-abdominal computed tomography (CT),
cerebral CT or magnetic resonance imaging, and isotonic
bone scanning. Positron emission tomography ([18F]-FDG-
PET)was frequently used in recent years. Bronchoscopywas
performed to confirm the diagnosis of malignancy and to
observe the extent of tumor invasion to the bronchus. Sus-
pected hilar and mediastinal lymph nodal involvements by
CT or FDG-PET were confirmed pathologically by endo-
bronchial ultrasound-guided transbronchial needle aspira-
tion [17]. Patients were staged according to the TNM
classification before the treatment. In this study, all patients
were reassessed with the new 7th TNM edition. From 2008,
induction therapy, especially chemoradiotherapy, was
introduced for the patients with central tumors or tumors
with pathologically positive mediastinal nodal involvement.
All induction chemotherapy and chemoradiotherapy
protocols were platinum based, but were combined with a
variety of other agents: oral S-1 in 14 patients, gemcitabine in
2 patients, paclitaxel in 2 patients, paclitaxel plus beva-
cizumab in 2 patients. Radiotherapy was given concurrently
with chemotherapy.
Surgical resection was performed using standard sur-
gical techniques with dissection of systematic hilar and
mediastinal lymph nodes. SL was performed whenever
technically and oncologically feasible, even for patients
with sufficient pulmonary function. Frozen sections of the
resected bronchial or vascular margins were always
examined to ensure complete resection. The bronchial
stump was routinely covered with a pedicled flap of
pericardial fat or intercostal muscle in patients who
underwent bronchial SL. Resection was defined as com-
plete (R0) if all gross disease was removed and if all
surgical margins were free of tumor cells. Incomplete
resection (R1 and R2) indicated that surgical margins
were microscopically positive (R1) or macroscopically
positive (R2).
Patient demographics were compared between groups
by t test for continuous variables (mean and standard
deviations) and v2 analysis for categorical variables (fre-
quency and percentages) as appropriate. Survival was
calculated from the date of surgery until the date of death
(due to any cause) or last follow-up (censored). Survival
curves were created using the Kaplan–Meier method, and
statistically significant differences between survival curves
were examined using log-rank tests. A p value derived
from two-tailed tests of less than or equal to 0.05 was
considered significant. All data were analyzed using JMP,
version 5.0 (SAS Institute, Inc., Cary, NC).
Results
Patient characteristics
Patients’ clinical characteristics according to the type of
surgery (PN or SL) are shown in Table 1. There were no
significant differences in age, sex, histology, and smoking
status between the groups. However, patients who under-
went PN had a significantly advanced pathological stage,
advanced pathological lymph nodal status, and a larger
tumor size than those who underwent SL. In terms of
pathological stage, 44 of 54 patients (81 %) in the PN
group were stage III–IV, while 60 of 151 patients (39 %) in
the SL group were stage III–IV. The preoperative FEV1 of
PN group was significantly worse than that of SL group.
This is because we perform SL to avoid PN even for
patients with sufficient pulmonary function. Both groups
achieved high complete resection rate. Eighteen of 151
(12 %) patients in the SL group received induction therapy,
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consisting of chemoradiotherapy in 16 patients and
chemotherapy in 2 patients, while only 2 of 54 (4 %)
patients in the PN group had induction chemotherapy
(p = 0.057). Three patients (5.6 %) in the PN group and 31
patients (20.5 %) in the SL group were eligible for adju-
vant therapy (p = 0.028).
Table 2 shows the types of SL and lung resection that
were performed. The most frequent procedure was bron-
chial SL (n = 74, 49 %), followed by vascular SL (n = 43,
28.5 %) and broncho-vascular SL (n = 34, 22.5 %).
Regarding lung resection, the right upper lobe was the most
frequent area resected (n = 52, 34.4 %). Extended SL
resection involving more than one lobe was achieved in 27
patients (17.9 %).
Mortality and morbidity
Table 3 shows postoperative mortality and morbidity.
Patients who underwent PN had significantly higher 30-day
(3.7 vs. 0 %, p = 0.018) and 90-day (13.0 vs. 1.3 %.
Table 1 Patient characteristics
Variables PN (n = 54) SL (n = 151) p
n (%) n (%)
Age (mean ± SD) 62.8 ± 8.9 63.8 ± 9.3 0.40
Sex
Male 42 (78) 122 (81) 0.64
Female 12 (22) 29 (19)
Smoker 44 (81) 116 (77) 0.76
Histologies 0.85
Adenocarcinoma 17 (31) 45 (30)
Squamous cell carcinoma 31 (57) 84 (56)
Large cell carcinoma 2 (4) 8 (5)
Other 4 (7) 14 (9)
Tumor diameter (mm) 0.0055*
Median (range) 55 (20–180) 42 (7–113)
Tumor side
Right/left 25/29 84/67
Preoperative FEV1 (L) (mean ± SD) 2.05 ± 0.64 2.27 ± 0.65 0.04*
Preoperative FEV1% (%), (mean ± SD) 74.2 ± 9.51 73.1 ± 9.84 0.45
pStages 0.0001*
IA/IB 2 (4) 43 (28)
IlA/IlB 7 (13) 47 (31)
IIIA/IIB 39 (72) 55 (36)
IV 5 (9) 5 (3)
Unknown 1 (2) 1 (1)
pNodal status 0.0001*
N0 6 (11) 60 (40)
N1 14 (26) 47 (31)
N2 30 (56) 41 (27)
N3 2 (4) 2 (1)
Unknown 2 (4) 1 (1)
Induction therapy 2 (4) 18 (12) 0.057
Adjuvant therapy 3 (6) 31 (21) 0.028*
Completeness of resection 0.18
Complete resection 51 (96) 141 (93)
Incomplete resection 2 (4) 10 (7)
PN pneumonectomy, SL sleeve lobectomy, SD standard deviation, FEV1 forced expiratory volume in 1 s
* Statistically significant
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p = 0.0003) mortality rates than those who underwent SL.
Two of 54 patients in the PN group died within 30 days: 1
patient died from a myocardial infarction followed by acute
respiratory distress syndrome (ARDS), and the other died
from a bronchial fistula with empyema followed by ARDS.
An additional five patients in the PN group died within
90 days from ARDS in two patients, interstitial pneumonia
in one patient, and tumor recurrence in two patients. Two
of 151 patients in the SL group died within 90 days: one
patient died from a bronchial fistula with empyema, and the
other died from pneumonia. In terms of morbidity, there
were no statistically significant differences in the rate of
major (16.7 vs. 9.1 %, p = 0.19) and minor (25.9 vs.
23.2 %, p = 0.68) complications between groups.
Survival
The median follow-up time for the 54 patients in the PN
group was 27.2 months (range 0.6–126.5 months), while
that for the 151 patients in the SL group was 44.2 months
(range 0.4–162 months). The overall 5-year survival rate of
the patients in the SL group was significantly higher than
that of the patients in the PN group (62.6 vs. 35.6 %,
respectively; p = 0.0007, Fig. 1). Part of this difference
was explained by the significantly advanced pathological
stage, advanced pathological lymph nodal status, and
higher postoperative mortality of the patients in the PN
group. Among patients with pN0–1 disease, the 5-year
survival rate after SL (n = 107) and PN (n = 20) was 71.5
Table 2 Types of SL and lung resection
Lung resection Bronchial SL (n = 74) Vascular SL (n = 43) Broncho-vascular SL (n = 34) Total (n = 151)
RUL 36 4 12 52
RML 4 0 0 4
RLL 9 1 0 10
RUML 2 2 1 5
RMLL 3 3 2 8
RUL ? S6 1 1 2 4
RUML ? S6 0 0 1 1
LUL 6 28 7 41
LLL 9 3 5 17
LUL ? S6 0 1 2 3
LLL ? S4/5 4 0 2 6
SL sleeve lobectomy, RUL right upper lobe, RML right middle lobe, RLL right lower lobe, RUML right upper and middle lobes, RMLL right
middle and lower lobes, S6 superior segment, LUL left upper lobe, LLL left lower lobe, S4/5 lingular segment
Table 3 Mortality and morbidity
Variables PN (n = 54) SL (n = 151) p
n (%) n (%)
30-day mortality 2 (3.7) 0 0.018*
90-day mortality 7 (13.0) 2 (1.3) 0.0003*
Major complications 9 (16.7) 15 (9.1) 0.19
Broncho-pleural fistula 3 (5.6) 6 (4.0) 0.62
Empyema 3 (5.6) 8 (5.3) 0.30
ARDS 5 (9.3) 4 (2.6) 0.052
Postoperative bleeding 1 (1.9) 0 0.094
Recurrent nerve palsy 0 1 (0.66) 0.55
Gastrointestinal hemorrhage 0 1 (0.66) 0.55
Myocardial infarction 2 (3.7) 1 (0.66) 0.12
Minor complications 14 (25.9) 35 (23.2) 0.68
Arrhythmia 12 (22.2) 23 (15.2) 0.24
Pneumonia 3 (5.6) 20 (13.2) 0.12
PN pneumonectomy, SL sleeve lobectomy, ARDS acute respiratory distress syndrome
* Statistically significant
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and 42.8 %, respectively (p = 0.011, Fig. 2a). In contrast,
there was no difference in survival between SL (n = 43)
and PN (n = 32) for patients with pN2–3 (42.6 vs. 28.5 %,
respectively; p = 0.35, Fig. 2b). In terms of pathological
stage, there was no survival difference between groups for
patients with stage I–II (p = 0.34) and stage III–IV
(p = 0.23).
Recurrence
Data were available for only 107 patients (19 patients in the
PN group and 88 patients in the SL group) who underwent
surgery from 2003 to 2013. Eight of 19 patients in the PN
group (42.1 %) had recurrence, consisting of systemic
recurrence in 5 patients (26.3 %), local recurrence in 2
patients (10.5 %), and both systemic and local recurrence
in 1 patient (5.3 %), while 38 of 88 patients (43.2 %) in the
SL group had recurrence, consisting of systemic recurrence
in 23 patients (26.1 %), local recurrence in 10 patients
(11.4 %), and both systemic and local recurrence in 5
patients (5.7 %).
Trends in surgical procedures and the PN:SL ratio
Table 4 shows the trends in surgical procedures during the
20-year study period, which was divided into four periods
of 5 years each. The ratio of PN among total surgeries
decreased significantly over the four periods (1994–1998,
1999–2003, 2004–2008, and 2009–2013) from 5.63 % to
3.17, 1.40, and 1.38 %, respectively (p\ 0.0001). The
ratio of SL among total surgeries also decreased from the
first (1994–1998) to the third (2004–2008) period from
9.20 to 7.94 and 5.20 %. These declines may reflect the
increase of small peripheral lung cancer in recent years.
However, the ratio of SL increased in the last period
(2009–2013) to 7.53 %. The PN:SL ratio increased sig-
nificantly over the four periods from 1.64 to 2.50, 3.71, and
5.44, respectively (p = 0.041) and the average was 2.80.
During the last period (2009–2013), when we introduced
induction therapy for patients with central tumors or with
mediastinal nodal involvement, 38 of 651 who received
surgery underwent induction therapy. The PN:SL ratios of
those who did and did not undergo induction therapy were
15 (PN: 1, SL: 15) and 4.25 (PN: 8, SL: 34), respectively
(p = 0.25).
Discussion
In the present study, we reviewed the evolution of a lung-
sparing strategy for NSCLC over 20 years in a single
institution. The ratio of PN among total surgeries decreased
significantly, while the PN:SL ratio increased significantly
over the study period. Induction therapy appeared to con-
tribute to the increase in the PN:SL ratio. Long-term sur-
vival in patients with pN0–1 was significantly better in the
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Fig. 1 Overall survival of 151 patients who underwent sleeve
lobectomy (SL) and 54 patients who underwent pneumonectomy
(PN). The 5-year survival rate was 62.6 versus 35.6 % with SL and
PN, respectively (p = 0.0007)


















p = 0.35 
Fig. 2 a Overall survival of
107 patients who underwent SL
and 20 patients who underwent
PN with pN0–1. The 5-year
survival rate was 71.5 and
42.8 % with SL and PN,
respectively (p = 0.011).
b Overall survival of 43 patients
who underwent SL and 32
patients who underwent PN
with pN2–3. The 5-year survival
rate was 42.6 and 28.5 % with
SL and PN, respectively
(p = 0.35)
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SL group than in the PN group, and postoperative mortality
and morbidity were significantly lower in the SL group
than in the PN group.
The application of SL has been extended to patients with
sufficient pulmonary function as a lung parenchyma-spar-
ing strategy that aims to decrease postoperative mortality
and morbidity and to improve long-term outcomes. The
operative risk of PN is still high, with mortality rates
ranging from approximately 5 to 10 % in recent reports,
despite the improvements in surgical techniques and post-
operative care [18–21]. In addition, in terms of quality of
life, Balduyck et al. evaluated quality of life after SL and
PN prospectively and concluded that SL offers better
quality of life than does PN in terms of dyspnea, pain, and
shoulder dysfunction [21]. Martin-Ucar and colleagues
demonstrated in their prospective study of parenchymal-
sparing lung surgery that the rate of PN could decrease
significantly with increasing use of SL [22].
We have been trying to avoid PN by making full use of
broncho-vascular reconstruction. The ratio of PN among
total surgeries for NSCLC was 2.64 % throughout the
study period, and it decreased to less than 1.5 % in the past
10 years. According to recent reports using the national
database, the ratio of PN among surgeries for NSCLC was
7.2–12.3 % [18, 19, 23]. Even in the institutes aggressively
pursuing SL, the ratio of PN was 4.3–17.6 % [22]. We
speculate that one of the reasons for this low PN rate other
than aggressive use of SL is the increase of small periph-
eral lung cancer in recent years, especially in Japan.
Another reason would be the aggressive use of extended
SL in recent years. In our study, extended SL was per-
formed in 27 patients. Twenty-one of those 27 patients
underwent extended SL in recent 10 years, and it appeared
to contribute to decrease the PN substantially. Very few
studies have reported the outcomes of extended SL [11, 12,
24, 25]. The number of patients who underwent extended
SL in these reports ranged from 15 to 27.
Go´mez-Caro and coworkers reported their aggressive
policy of PN avoidance and showed that the PN:SL ratio
can be used as a quality standard and that the ratio should
be at least 1.5 or 2 [13]. Regarding the PN:SL ratio, the
present study demonstrated an increased PN:SL ratio to
more than 5 in the last period and the average was 2.8. This
PN:SL ratio is extremely high, taking into consideration
that the PN:SL ratio reported by Go´mez-Caro and col-
leagues was 2.6, which was the highest in their review. The
possible factors contributing to our high PN:SL ratio may
be the use of induction therapy in addition to the decrease
of PN which was described before. Since we introduced
induction therapy for the patients with central tumors or
tumors with pathologically proven clinical N2 in 2008, the
PN:SL ratio increased dramatically. During the last
5 years, the PN:SL ratios of those who underwent induc-
tion therapy were higher than the ratios of those who did
not, although the difference was not significant. Rendina
et al. reported that only 5 of 68 patients (7.3 %) who
received induction chemotherapy underwent PN, while 27
patients (39.7 %) underwent broncho-vascular reconstruc-
tive surgery, which results in a PN:SL ratio of 5.4 [16].
They suggested that the need for PN could be reduced by
induction therapy while maintaining the same rates of
radical treatment and survival. Since most of our cases that
received induction therapy were observed for less than
5 years, we must follow these cases carefully.
One of the major concerns with SL is locoregional
recurrence. According to the recent meta-analysis by Shi
et al., the pooled locoregional recurrence with SL was
14.44 % compared with 26.08 % with PN, which was not
statistically significant [8]. In our study, although data were
only available for patients who underwent surgery in the
past 11 years, the locoregional recurrence rates of SL and
PN were 17.1 and 15.8 %, respectively, which are almost
consistent with previous reports that showed similar local
recurrence rates between SL and PN [1, 3, 6].
Our study has some limitations. It is retrospective, and it
had a long time interval of patient recruitment that had
changes in the treatment of lung cancer. In addition, the
results of recurrence were only available in 52.2 % of
patients. Another limitation is that since PN was signifi-
cantly associated with advanced disease compared with SL,
Table 4 Numbers of surgeries by type during the study period
Procedures 1994–1998 1999–2003 2004–2008 2009–2013 Total
Total surgery 391 504 501 651 2047
Pneumonectomy 22 (5.63 %) 16 (3.17 %) 7 (1.40 %) 9 (1.38 %) 54 (2.64 %)
Induction therapy 0 1 0 1 2
Sleeve lobectomy 36 (9.20 %) 40 (7.94 %) 26 (5.20 %) 49 (7.53 %) 151 (7.38 %)
Induction therapy 0 0 3 15 18
PN:SL ratio 1.64 2.50 3.71 5.44 2.80
PN pneumonectomy, SL sleeve lobectomy
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the difference in outcomes between groups was associated
with selection bias. Therefore, our findings should be
interpreted with caution.
In conclusion, this study demonstrated the actual evo-
lution of a lung-sparing strategy over 20 years in a single
institution. A lung-sparing strategy with SL could decrease
the ratio of PN substantially, with less mortality. Induction
therapy may facilitate SL and increase the PN:SL ratio.
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